Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Aczone® (dapsone) – Expanded indication
September 10, 2019 - The FDA approved Almirall’s Aczone (dapsone) gel 7.5%, for the topical treatment of acne vulgaris in patients 9 years of age and older.
